Display options
Cite
Garza D, Kandathil A, Xi Y, et al. 18F-fluciclovine PET/CT detection of biochemical recurrent prostate cancer in patients with PSA levels <2.00 ng/mL. Nucl Med Commun. 2021;42(8):907-913doi: 10.1097/MNM.0000000000001412.
Garza, D., Kandathil, A., Xi, Y., & Subramaniam, R. M. (2021). 18F-fluciclovine PET/CT detection of biochemical recurrent prostate cancer in patients with PSA levels <2.00 ng/mL. Nuclear medicine communications, 42(8), 907-913. https://doi.org/10.1097/MNM.0000000000001412
Garza, Daniel, et al. "18F-fluciclovine PET/CT detection of biochemical recurrent prostate cancer in patients with PSA levels <2.00 ng/mL." Nuclear medicine communications vol. 42,8 (2021): 907-913. doi: https://doi.org/10.1097/MNM.0000000000001412
Garza D, Kandathil A, Xi Y, Subramaniam RM. 18F-fluciclovine PET/CT detection of biochemical recurrent prostate cancer in patients with PSA levels <2.00 ng/mL. Nucl Med Commun. 2021 Aug 01;42(8):907-913. doi: 10.1097/MNM.0000000000001412. PMID: 33741863.
Copy Download .nbib Format: NLM
Share it on

Nucl Med Commun. 2021 Aug 01;42(8):907-913. doi: 10.1097/MNM.0000000000001412.

18F-fluciclovine PET/CT detection of biochemical recurrent prostate cancer in patients with PSA levels <2.00 ng/mL.

Nuclear medicine communications

Daniel Garza, Asha Kandathil, Yin Xi, Rathan M Subramaniam

Affiliations

  1. UT Southwestern: The University of Texas Southwestern Medical Center, Dallas, Texas, USA.

PMID: 33741863 DOI: 10.1097/MNM.0000000000001412

Abstract

OBJECTIVE: To establish the detection rate of prostate cancer recurrence following definitive therapy by 18F-fluciclovine PET/computed tomography (CT) in patients with biochemical recurrence (BCR) and prostate-specific antigen (PSA) levels less than 2.00 ng/mL.

METHODS: In this retrospective study, 78 patients with a PSA level of less than 2.00 ng/mL were selected from the 211 patients who underwent at least one 18F-fluciclovine PET/CT scan at our institution for the detection of biochemical recurrent prostate cancer between April 2017 and December 2018. Inherent differences in the characteristics of patients with and without a positive scan were investigated for possible associations using multivariable analysis.

RESULTS: One or more positive sites of recurrence were identified in 44 out of 78 patients (56.4%). Patients with a Gleason score between 8 and 10 were more likely to have a positive scan compared to patients with Gleason scores of 6-7 [adjusted odds ratio: 3.53, 95% confidence interval (1.13-10.99), P = 0.03]. No other significant association was found between PSA, T classification, and detection rate.

CONCLUSION: 18F-fluciclovine PET/CT demonstrated a detection rate of 56.4% among patients with a PSA below 2.0 ng/mL. The results of this study support the use of 18F-fluciclovine PET/CT for the detection of recurrent prostate cancer at lower PSA levels, even at PSA levels less than 0.5 ng/mL.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

References

  1. Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health. 2018; 12:1807–1823. - PubMed
  2. Kolodziej M. Management of biochemically recurrent prostate cancer following local therapy. Am J Manag Care. 2014; 20:S273–S281. - PubMed
  3. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007; 177:540–545. - PubMed
  4. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65:965–974. - PubMed
  5. Chang AJ, Autio KA, Roach M 3rd, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014; 11:308–323. - PubMed
  6. Savir-Baruch B, Zanoni L, Schuster DM. Imaging of prostate cancer using fluciclovine. Urol Clin North Am. 2018; 45:489–502. - PubMed
  7. Rayn KN, Elnabawi YA, Sheth N. Clinical implications of PET/CT in prostate cancer management. Transl Androl Urol. 2018; 7:844–854. - PubMed
  8. Xu KM, Chen RC, Schuster DM, Jani AB. Role of novel imaging in the management of prostate cancer. Urol Oncol. 2019; 37:611–618. - PubMed
  9. Özgür BC, Gültekin S, Ekici M, Yilmazer D, Alper M. A narrowing range of bone scan in newly diagnosed prostate cancer patients: a retrospective comparative study. Urol Ann. 2015; 7:193–198. - PubMed
  10. McArthur C, McLaughlin G, Meddings RN. Changing the referral criteria for bone scan in newly diagnosed prostate cancer patients. Br J Radiol. 2012; 85:390–394. - PubMed
  11. England JR, Paluch J, Ballas LK, Jadvar H. 18F-fluciclovine PET/CT detection of recurrent prostate carcinoma in patients with serum PSA ≤ 1 ng/mL after definitive primary treatment. Clin Nucl Med. 2019; 44:e128–e132. - PubMed
  12. Parent EE, Schuster DM. Update on 18F-fluciclovine PET for prostate cancer imaging. J Nucl Med. 2018; 59:733–739. - PubMed
  13. Savir-Baruch B, Banks KP, McConathy JE, Molchanova-Cook OP, Parent EE, Takalkar A, et al. ACR-ACNM practice parameter for the performance of fluorine-18 fluciclovine-PET/CT for recurrent prostate cancer. Clin Nucl Med. 2018; 43:909–917. - PubMed
  14. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008; 35:18–23. - PubMed
  15. Nanni C, Schiavina R, Brunocilla E, Boschi S, Borghesi M, Zanoni L, et al. 18F-fluciclovine PET/CT for the detection of prostate cancer relapse: a comparison to 11C-choline PET/CT. Clin Nucl Med. 2015; 40:e386–e391. - PubMed
  16. Odewole OA, Tade FI, Nieh PT, Savir-Baruch B, Jani AB, Master VA, et al. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT. Eur J Nucl Med Mol Imaging. 2016; 43:1773–1783. - PubMed
  17. Giovacchini G, Guglielmo P, Mapelli P, Incerti E, Gajate AMS, Giovannini E, et al. 11C-choline PET/CT predicts survival in prostate cancer patients with low PSA <1 NG/ml. Eur J Nucl Med Imaging. 2019; 49:921–929. - PubMed
  18. Smith CP, Laucis A, Harmon S, Mena E, Lindenberg L, Choyke PL, Turkbey B. Novel imaging in detection of metastatic prostate cancer. Curr Oncol Rep. 2019; 21:31. - PubMed
  19. Chau A, Gardiner P, Colletti PM, Jadvar H. Diagnostic performance of 18F-fluciclovine in detection of prostate cancer bone metastases. Clin Nucl Med. 2018; 43:e226–e231. - PubMed
  20. De Visschere PJL, Standaert C, Fütterer JJ, Villeirs GM, Panebianco V, Walz J, et al. A systematic review on the role of imaging in early recurrent prostate cancer. Eur Urol Oncol. 2019; 2:47–76. - PubMed
  21. Gusman M, Aminsharifi JA, Peacock JG, Anderson SB, Clemenshaw MN, Banks KP. Review of 18F-fluciclovine PET for detection of recurrent prostate cancer. Radiographics. 2019; 39:822–841. - PubMed
  22. Team RC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. http://www.R-project.org/. - PubMed
  23. Tourinho-Barbosa R, Srougi V, Nunes-Silva I, Baghdadi M, Rembeyo G, Eiffel SS, et al. Biochemical recurrence after radical prostatectomy: what does it mean? Int Braz J Urol. 2018; 44:14–21. - PubMed
  24. Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, et al. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study. BJU Int. 2015; 115:874–883. - PubMed
  25. Savir-Baruch B, Lovrec P, Solanki AA, Adams WH, Yonover PM, Gupta G, Schuster DM. Fluorine-18-labeled fluciclovine PET/CT in clinical practice: factors affecting the rate of detection of recurrent prostate cancer. AJR Am J Roentgenol. 2019; 213:851–858. - PubMed
  26. Bach-Gansmo T, Nanni C, Nieh PT, Zanoni L, Bogsrud TV, Sletten H, et al. Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine (18F) positron emission tomography/computerized tomography imaging in the staging of biochemically recurrent prostate cancer. J Urol. 2017; 197:676–683. - PubMed
  27. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019; 20:1286–1294. - PubMed

MeSH terms

Publication Types